AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2283715
Drug: Cefdinir granules
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir granules at a dose of 6 mg/kg
Trial: 2283715
Drug: Cefdinir granules
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefdinir granules at daily doses of 9.0‐20.7 mg/kg in 3 divided portions
Trial: 31510721
Drug: Bilateral PC6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral PC6 sham injection of 0.9% sodium chloride + intravenous granisetron (Group A, n=31)
Trial: 31510721
Drug: Bilateral acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral acupuncture point injection at PC6 of 0.9% sodium chloride + intravenous 0.9% sodium chloride (Group B, n=33)
Trial: 31510721
Drug: Bilateral acupuncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral acupuncture point injection at PC6 of 0.9% sodium chloride + intravenous granisetron (Group C, n=30)
Trial: 25890480
Drug: Cellular immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular immunotherapy (CIT) with autologous natural killer cells, γδT cells, and cytokine‐induced killer cells in combination with chemotherapy
Trial: 25890480
Drug: Cellular immunotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cellular immunotherapy (CIT) with chemotherapy
Trial: 23487517
Drug: Betrixaban 40
RxNorm normalized name: betrixaban 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betrixaban 40 mg once daily
Trial: 23487517
Drug: Betrixaban 60
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Betrixaban 60 mg once daily
Trial: 23487517
Drug: Betrixaban 80
RxNorm normalized name: betrixaban 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Betrixaban 80 mg once daily
Trial: 23487517
Drug: Warfarin (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (adjusted to INR 2.0-3.0)
Trial: 8191242
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 100 mg bid for 5 days (n = 113)
Trial: 8191242
Drug: Phenoxymethyl penicillin
RxNorm normalized name: Phenoxymethyl Penicillin
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenoxymethyl penicillin 600 mg tid for 10 days (n = 107)
Trial: 12855349
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream and oral glucose (1 ml of glucose at 300 mg/ml)
Trial: 12855349
Drug: EMLA cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EMLA cream and oral glucose
Trial: 12855349
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream and water
Trial: 10100592
Drug: Granisetron injection
RxNorm normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron injection (40 microg/kg) via 30-min infusion
Trial: 10100592
Drug: Granisetron injection
RxNorm normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron injection (40 microg/kg) via slow intravenous injection over 30 s
Trial: 10100592
Drug: Granisetron injection
RxNorm normalized name: granisetron Injection
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron injection (40 microg/kg) via 30-min infusion and slow intravenous injection
Trial: 8739815
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen administered (normoxaemia)
Trial: 26252749
Drug: Amoxicillin 2
RxNorm normalized name: amoxicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 2 g
Trial: 23718900
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg vinorelbine, taken orally three times a week
Trial: 23718900
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg vinorelbine, taken orally three times a week
Trial: 23718900
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg vinorelbine, taken orally three times a week
Trial: 23718900
Drug: Low pre-treatment
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low pre-treatment blood concentrations of FGF2 and IL8
Trial: 19411056
Drug: Nutrition education
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutrition education and gardening (NE+G)
Trial: 17539707
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using a laser source with a wavelength of 690 nm associated with a phenothiazine photosensitizer
Trial: 7917929
Drug: Tamoxifen and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen and prednisolone, 7.5 mg daily
Trial: 28263288
Drug: Adjuvanted influenza
RxNorm normalized name: Influenza, adjuvanted, quadrivalent, PF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted influenza vaccine (MF59)
Trial: 26814087
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose group (Group A)
Trial: 8822656
Drug: High-dose oxytocin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose oxytocin (2.5 mU/minute initial dose, increments of 2.5 mU/minute)
Trial: 8822656
Drug: Low-dose oxytocin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oxytocin (1.25 mU/minute initial dose, increments of 1.25 mU/minute)
Trial: 4061901
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg lidocaine intravenously
Trial: 4061901
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg lidocaine intravenously
Trial: 4061901
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg lidocaine intravenously
Trial: 4061901
Drug: 2.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg/kg lidocaine intravenously
Trial: 4061901
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg lidocaine intravenously
Trial: 25612603
Drug: RATG (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RATG (0.5 mg/kg/day)
Trial: 25612603
Drug: RATG plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RATG plus basiliximab (20 mg on days 0 and 4)
Trial: 25612603
Drug: AZA therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZA therapy
Trial: 25612603
Drug: MMF therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMF therapy
Trial: 17524873
Drug: Oral valgancyclovir
RxNorm normalized name: valganciclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valgancyclovir for 2 weeks (VAL2w)
Trial: 17524873
Drug: Oral valgancyclovir
RxNorm normalized name: valganciclovir Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral valgancyclovir for 3 months (VAL3m)
Trial: 17524873
Drug: Intravenous gancyclovir
RxNorm normalized name: Gancyclovir
DrugBank: Ganciclovir (DB01004)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous gancyclovir for 2 weeks (GAN)
Trial: 9526931
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg oral diazepam
Trial: 11271312
Drug: Higher oral
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher oral FK 506 dose (0.19 mg/kg bw per day) in early phase of multicenter trial
Trial: 11271312
Drug: Lower oral
RxNorm normalized name: melatonin/val/chamomile flower ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower oral FK 506 dose (0.14 mg/kg bw per day) in late phase of multicenter trial
Trial: 11271312
Drug: Further reduced
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Further reduced FK 506 dosage (0.10 mg/kg bw per day or less) in recent single centre treatment
Trial: 2459543
Drug: Felodipine 1
RxNorm normalized name: felodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 1 mg intravenous infusion
Trial: 2459543
Drug: Felodipine 3
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 3 mg intravenous infusion
Trial: 2459543
Drug: Felodipine 5
RxNorm normalized name: felodipine 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine 5 mg oral solution
Trial: 2459543
Drug: Felodipine 15
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 15 mg oral solution
Trial: 2459543
Drug: Felodipine 40
RxNorm normalized name: Felodipine
DrugBank: Felodipine (DB01023)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felodipine 40 mg oral solution
Trial: 15784645
Drug: Conventional Control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Control (CC)
Trial: 30942007
Drug: Oral mecobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mecobalamin dispersible tablets and multivitamin B tablets within 3 days after onset, acupuncture started from the 4th day (Group B)
Trial: 30942007
Drug: Oral mecobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mecobalamin dispersable tablets and multivitamin B tablets within 5 days after onset, acupuncture from the 6th day (Group C)
Trial: 30942007
Drug: Oral mecobalamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral mecobalamin dispersable tablets and multivitamin B tablets within 7 days after onset, acupuncture from the 8th day (Group D)
Trial: 21663717
Drug: Preoperative interscalene
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative interscalene block with 30 mL of 0.5% ropivacaine
Trial: 21663717
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 10 mL of saline solution
Trial: 9241285
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (2000 mg/day)
Trial: 3549507
Drug: Sclerotherapy (1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sclerotherapy (1% polidocanol, performed twice weekly until varices eradicated)
Trial: 3549507
Drug: Propranolol (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (twice daily, mean dose 161 +/- 80 mg per day)
Trial: 26763851
Drug: Losartan potassium
RxNorm normalized name: Losartan Potassium
DrugBank: Losartan (DB00678)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Losartan potassium tablets (50‐100 mg per day)
Trial: 26763851
Drug: Levamlodipine besylate
RxNorm normalized name: Levamlodipine besylate
DrugBank: Levamlodipine (DB09237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levamlodipine besylate tablets (2.5‐5.0 mg per day)
Trial: 25068412
Drug: Fascia iliaca
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia iliaca compartment block (FICB) using 40 mL ropivacaine 0.5%
Trial: 25068412
Drug: Intravenous fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous fentanyl (IVFE) 1.5 μg/kg
Trial: 22709704
Drug: Baked beetroot
RxNorm normalized name: BAKING POWDER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baked beetroot (200 g with ≥500 mg nitrate)
Trial: 18626166
Drug: Metoclopramide 10
RxNorm normalized name: metoclopramide 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide 10 mg and Normal saline (Group C)
Trial: 15728536
Drug: Animal compound-free
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Animal compound-free (ACF) medium
Trial: 12574563
Drug: Dexamphetamine (2.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamphetamine (2.5, 5, or 10 mg orally twice daily)
Trial: 7028085
Drug: Simultaneous timolol
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Simultaneous timolol and epinephrine treatment
Trial: 31674920
Drug: Daily emotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily emotion ratings (control group)
Trial: 26154926
Drug: Ferric pyrophosphate
RxNorm normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric pyrophosphate citrate (FPC) administered via dialysate (2 μmol/l of iron)
Trial: 26154926
Drug: Ferric pyrophosphate
RxNorm normalized name: Ferric Pyrophosphate
DrugBank: Ferric pyrophosphate citrate (DB13995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferric pyrophosphate citrate (FPC) administered via dialysate
Trial: 21084403
Drug: Intravenous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous insulin treatment (IIT) for 24 hours targeting glycemia less than 110 mg/dl
Trial: 21084403
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST) with regular insulin if glycemia was greater than 200 mg/dl
Trial: 17289894
Drug: Cetuximab 250
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab 250 mg/m2 (weekly)
Trial: 17289894
Drug: Cetuximab (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (single doses of 250-500 mg/m2)
Trial: 17289894
Drug: Cetuximab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (various single doses: 50, 100, 250, 400, 500 mg/m2)
Trial: 17289894
Drug: Cetuximab (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cetuximab (250 mg/m2)
Trial: 15498524
Drug: Dimethylglycine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dimethylglycine (400 mg daily for 28 days)
Trial: 15498524
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 28 days)
Trial: 14563654
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/day orally)
Trial: 30054895
Drug: Ceftazidime 2000-500
RxNorm normalized name: ceftazidime 2000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime 2000-500 mg every 8 hours
Trial: 30054895
Drug: Avibactam 2000-500
RxNorm normalized name: avibactam 500 MG / ceftazidime 2000 MG [Avycaz]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avibactam 2000-500 mg every 8 hours
Trial: 26757276
Drug: Three-dose intramuscular
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose intramuscular (i.m.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Trial: 26757276
Drug: Three-dose intravenous
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose intravenous (i.v.) artesunate regimen (4 mg/kg at 0, 24, and 48 hours)
Trial: 26757276
Drug: Five-dose intramuscular
RxNorm normalized name: fivehorn smotherweed pollen extract
DrugBank: Bassia hyssopifolia pollen (DB10941)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Five-dose intramuscular (i.m.) artesunate regimen (2.4 mg/kg at 0, 12, 24, 48, and 72 hours)
Trial: 24216034
Drug: darunavir/ritonavir 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 800/100 mg once daily monotherapy
Trial: 24216034
Drug: darunavir/ritonavir 800/100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: darunavir/ritonavir 800/100 mg once daily + two NRTIs
Trial: 22278424
Drug: Cabergoline monotherapy
RxNorm normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cabergoline monotherapy (0.5 mg once daily for 18 weeks)
Trial: 22278424
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of cabergoline and pegvisomant (10 mg daily for 12 weeks)
Trial: 22278424
Drug: Pegvisomant (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pegvisomant (10 mg daily after cabergoline withdrawal for 12 weeks)
Trial: 15774238
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement containing vitamin E, selenium, vitamin C, and coenzyme Q10
Trial: 12042275
Drug: Prednisolone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (10 mg/day in two divided doses for 4 weeks)
Trial: 9801994
Drug: Intralipid plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralipid plus heparin (250 ml 10% Intralipid plus 5000 U heparin)
Trial: 9801994
Drug: Acipimox (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acipimox (250 mg, orally, at 0 min and at 210 min)
Trial: 26474861
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of piperacillin–tazobactam (CI)
Trial: 26474861
Drug: Intermittent infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent infusion of piperacillin–tazobactam (II)
Trial: 27533787
Drug: Tedizolid (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tedizolid (200 mg once daily for 6 days)
Trial: 30242736
Drug: Linezolid (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Linezolid (600 mg twice daily for 10 days)
Trial: 14722206
Drug: BIIL 284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIL 284 25 mg
Trial: 14722206
Drug: BIIL 284
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIIL 284 150 mg
Trial: 9459192
Drug: Letrozole 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 0.5 mg p.o. once daily
Trial: 9459192
Drug: Letrozole 2.5
RxNorm normalized name: letrozole 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 2.5 mg p.o. once daily
Trial: 9459192
Drug: Letrozole (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (both doses combined)
Trial: 9459192
Drug: Letrozole (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole (both doses)
Trial: 3540835
Drug: Surfactant therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surfactant therapy (bovine surfactant, surfactant TA)
Trial: 26473443
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (continued daily activities)
Trial: 26215666
Drug: Immediate vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate vaccination of eligible adults with single dose vaccination
Trial: 23539885
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human follicle-stimulating hormone (rhFSH)
Trial: 23539885
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of progesterone in oil (PIO)
Trial: 15986229
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg body weight Roc (Roc group)
Trial: 15986229
Drug: 1.0 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 mg/kg succinylcholine (Sux; control group)
Trial: 12552184
Drug: Dolasetron 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron 12.5 mg intravenous
Trial: 12552184
Drug: Droperidol 0.625
RxNorm normalized name: droPERidol 0.625 mg/mL intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol 0.625 mg intravenous and dexamethasone 4 mg intravenous (control)
Trial: 10540047
Drug: Dalteparin sodium
RxNorm normalized name: Dalteparin Sodium
DrugBank: Dalteparin (DB06779)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin sodium 5000 units s.c. injection administered twice daily for 12 weeks
Trial: 1989365
Drug: Control (self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (self‐administered chest physiotherapy alone)
Trial: 6815974
Drug: Bupivacaine 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 50 mg (another 50 mg 4 h later)
Trial: 29703335
Drug: GEM-P (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEM-P (intravenous gemcitabine 1000 mg/m2 on days 1, 8, and 15, cisplatin 100 mg/m2 on day 15, and oral or intravenous methylprednisolone 1000 mg on days 1-5) every 28 days for four cycles
Trial: 29703335
Drug: CHOP (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHOP (intravenous cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, and vincristine 1·4 mg/m2 [maximum 2 mg] on day 1, and oral prednisolone 100 mg on days 1-5) every 21 days for six cycles
Trial: 18090045
Drug: Ritonavir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ritonavir (800 mg)
Trial: 18090045
Drug: Amprenavir (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amprenavir (1200 mg)
Trial: 11697387
Drug: Prophylactic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic treatment for unborn children
Trial: 9558288
Drug: IFN‐alpha2b (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN‐alpha2b (6 megaunits/m2 thrice weekly for 24 weeks)